The quest to overcome resistance to EGFR-targeted therapies in cancer.
The quest to overcome resistance to EGFR-targeted therapies in cancer.
复制标题
作者：
所有最初受益于表皮生长因子受体（EGFR）靶向治疗的转移性肺癌、结直肠癌、胰腺癌或头颈癌患者最终都会产生耐药性。对耐药机制的数量和复杂性的日益了解突出了杀死对EGFR抑制剂耐药的肿瘤的巨大挑战。我们对耐药途径不断增长的了解为开发新的基于机制的抑制剂和联合疗法提供了机会，以预防或克服肿瘤的治疗耐药性。我们对肺癌、结直肠癌和头颈癌EGFR靶向治疗的耐药途径进行了全面综述，并讨论了旨在规避耐药的治疗策略。
All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually develop resistance. An increasing understanding of the number and complexity of resistance mechanisms highlights the Herculean challenge of killing tumors that are resistant to EGFR inhibitors. Our growing knowledge of resistance pathways provides an opportunity to develop new mechanism-based inhibitors and combination therapies to prevent or overcome therapeutic resistance in tumors. We present a comprehensive review of resistance pathways to EGFR-targeted therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are designed to circumvent resistance.
登录
查看更多内容
影响因子：
17.1
作者：
Chmielecki J;Foo J;Oxnard GR;Hutchinson K;Ohashi K;Somwar R;Wang L;Amato KR;Arcila M;Sos ML;Socci ND;Viale A;de Stanchina E;Ginsberg MS;Thomas RK;Kris MG;Inoue A;Ladanyi M;Miller VA;Michor F;Pao W
通讯作者：
Pao W
影响因子：
7.3
作者：
Bean GR;Ganesan YT;Dong Y;Takeda S;Liu H;Chan PM;Huang Y;Chodosh LA;Zambetti GP;Hsieh JJ;Cheng EH
通讯作者：
Cheng EH
DOI：
10.1158/1078-0432.ccr-09-2345
发表时间：
2010-01-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Campoli M;Ferris R;Ferrone S;Wang X
通讯作者：
Wang X
影响因子：
6.7
作者：
Budha, N. R.;Frymoyer, A.;Ware, J. A.
通讯作者：
Ware, J. A.
影响因子：
28.2
作者：
Cheung HW;Du J;Boehm JS;He F;Weir BA;Wang X;Butaney M;Sequist LV;Luo B;Engelman JA;Root DE;Meyerson M;Golub TR;Jänne PA;Hahn WC
通讯作者：
Hahn WC